Aparito

national-cancer-institute-1fvqUP-xaYQ-unsplash.jpg

Aparito is a digital health company that enables the remote monitoring of patients during clinical drug trials for rare diseases.

Published

Key information

  • Focus area

    Early action
  • Investment type

    Enterprise equity
  • Region

    UK wide
  • Investment amount

    £70,000
  • Challenge

    There are over 6,000 rare diseases affecting 350 million people globally. Clinical trials for these diseases typically require regular and ongoing monitoring of patients through continuous hospital visits. Many of these trials are inconclusive due to a lack of data.

  • Approach

    Aparito has developed a technology platform (Atom5) consisting of a smartphone app and wearable devices to collect continuous patient-generated data remotely. This allows clinicians to monitor patients through the clinical trial outside of the hospital setting.

  • Revenue model

    The technology is purchased by a range of organisations involved in clinical trials such as bio-tech companies, pharmaceuticals, and clinical research organisations.

  • Impact

    The platform delivers relevant, real-time data to clinicians resulting in faster diagnosis, treatment, and drug development for rare diseases.

    It provides a unique opportunity to understand more accurately how a patient is feeling and functioning through the trials and reduces the burden on patients, with fewer hospital visits, tests and assessments.

Responding to COVID-19

  • For people undergoing cancer treatment, this is a particularly worrying time. Patients displaying any form of viral symptoms are assumed ‘potential virus-positive’ and risk contaminating other vulnerable patients during clinic visits. This risk is particularly high for cancer patients who are immunosuppressed and the need to reduce unplanned visits during the current pandemic is especially important.

  • Aparito was quick to respond to the crisis as its existing technology lends itself to supporting routine clinical care remotely. Having partnered with Betsi Cadwaladr University Health Board in Wales, Atom5 is now helping monitor up to 1,200 cancer patients, meaning they can stay at home whilst still receiving care and support remotely from their clinicians.

  • Over the last five years at Aparito we have deployed our Atom5 platform for supporting patient enrolment in clinical trials and research. The solution naturally lends itself to supporting routine clinical care and we are pleased that we can offer this to support.

    Dr Innominato

    Consultant Oncologist at Ysbyty Gwynedd

Related investment

Bethnal Green Ventures

Helping tech-for-good ventures launch and scale.

Learn more
BGV Portfolio company LettUs grow_02_Photo Credit_Jack Wiseall.jpg
Camilla Parke

Camilla Parke

Investment Director
Talk to me about:
Social Pensions, Employer savings and investment products, Retail investor insight, Corporate social investment

You may also be interested in

  • Third Space Learning 6.JPG

    Early action

    We want to tackle social issues at an early stage, either to stop them occurring or to prevent them from worsening.

    Learn more
  • Cherry Tree 4.jpg

    Creating new ideas

    We work with expert partners to create and design new investments.

    Learn more
  • Reboot West.jpg

    Impact

    Our approach to impact is deeply embedded in our investment process, decision making and portfolio management, making sure it runs through everything we do.

    Learn more